Literature DB >> 7493353

Threshold estimation in single photon emission computed tomography and planar imaging for clinical radioimmunotherapy.

Y E Erdi1, B W Wessels, M H Loew, A K Erdi.   

Abstract

Thresholding is the most widely used organ or tumor segmentation technique used in single photon emission computed tomography (SPECT) and planar imaging for monoclonal antibodies. Selecting the optimal threshold requires a priori knowledge (volumes from CT or magnetic resonance) for the size and contrast level of the organ in question. Failure to select an optimal threshold leads to overestimation or underestimation of the volume and, subsequently, the organ-absorbed dose value in radio-immunotherapy. To investigate this threshold selection problem, we performed a phantom experiment using six lucite spheres ranging from 1 to 117 ml and filled with a uniform activity of 1 microCi/ml Tc-99m. These spheres were placed at the center and off-center locations of a Jasczsak phantom and scanned with a three-headed gamma camera in SPECT and planar modes. Target-nontarget (T:NT) ratios were changed by adding the appropriate activity to the background. A threshold search algorithm with an interpolative background correction was applied to sphere images. This algorithm selects a threshold that minimizes the difference between the true and measured volumes (SPECT) or areas (planar). It was found that for spheres equal to or larger than 20 ml [diameter (D) > 38 mm] and T:NT ratios higher than 5:1, mean thresholds at 42% for SPECT and 38% for planar imaging yielded minimum image segmentation errors, which is in agreement with current literature. However, for small T:NT ratios (< 5:1), the threshold values as high as 71% for SPECT and 85% for planar imaging were substantially different than those fixed thresholds for large spheres (D > 38 mm). Hence, the use of fixed thresholds in low contrasts and with tumor and organ sizes of clinical interest (25 < or = D < or = 50 mm) may result in limited volume estimation accuracy. Therefore, we have provided the investigator a method to obtain the threshold values in which the proper threshold can be selected based on the organ and tumor size and image contrast. By measuring and calibrating the proper threshold value derived through machine-specific phantom measurements, a more accurate volume and activity quantitation can be performed. This, in turn, will provide tumor-absorbed dose optimization and greater accuracy in the measurement of potentially subacute, toxic absorbed doses to normal organs for patients undergoing radioimmunotherapy.

Entities:  

Mesh:

Year:  1995        PMID: 7493353

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy.

Authors:  Yuni K Dewaraja; Eric C Frey; George Sgouros; A Bertrand Brill; Peter Roberson; Pat B Zanzonico; Michael Ljungberg
Journal:  J Nucl Med       Date:  2012-06-28       Impact factor: 10.057

2.  Enhancing the utility of prostascint SPECT scans for patient management.

Authors:  Marilyn E Noz; Grace Chung; Benjamin Y Lee; Gerald Q Maguire; J Keith DeWyngaert; Jay V Doshi; Elissa L Kramer; Antoinette D Murphy-Walcott; Michael P Zeleznik; Noeun G Kwak
Journal:  J Med Syst       Date:  2006-04       Impact factor: 4.460

3.  Simplifying volumes-of-interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole-organ VOIs.

Authors:  Esther M Vicente; Martin A Lodge; Steven P Rowe; Richard L Wahl; Eric C Frey
Journal:  Med Phys       Date:  2017-03-28       Impact factor: 4.071

4.  A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin).

Authors:  Massimiliano Pacilio; Margherita Betti; Francesco Cicone; Carolina Del Mastro; Livia Montani; Laura Chiacchiararelli; Alessia Monaco; Enrico Santini; Francesco Scopinaro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

5.  Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation.

Authors:  A Schaefer; M Vermandel; C Baillet; A S Dewalle-Vignion; R Modzelewski; P Vera; L Massoptier; C Parcq; D Gibon; T Fechter; U Nemer; I Gardin; U Nestle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-14       Impact factor: 9.236

6.  MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications.

Authors:  Yuni K Dewaraja; Michael Ljungberg; Alan J Green; Pat B Zanzonico; Eric C Frey; Wesley E Bolch; A Bertrand Brill; Mark Dunphy; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels
Journal:  J Nucl Med       Date:  2013-10-15       Impact factor: 10.057

7.  Utility of Quantitative Tc-MAA SPECT/CT for yttrium-Labelled Microsphere Treatment Planning: Calculating Vascularized Hepatic Volume and Dosimetric Approach.

Authors:  Etienne Garin; Yan Rolland; Laurence Lenoir; Marc Pracht; Habiba Mesbah; Philippe Porée; Sophie Laffont; Bruno Clement; Jean-Luc Raoul; Eveline Boucher
Journal:  Int J Mol Imaging       Date:  2011-07-28

8.  SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy.

Authors:  Johan Gustafsson; Anna Sundlöv; Katarina Sjögreen Gleisner
Journal:  EJNMMI Res       Date:  2017-02-23       Impact factor: 3.138

9.  A 3D Monte Carlo Method for Estimation of Patient-specific Internal Organs Absorbed Dose for (99m)Tc-hynic-Tyr(3)-octreotide Imaging.

Authors:  Mehdi Momennezhad; Shahrokh Nasseri; Seyed Rasoul Zakavi; Ali Asghar Parach; Mahdi Ghorbani; Ruhollah Ghahraman Asl
Journal:  World J Nucl Med       Date:  2016 May-Aug

10.  Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.

Authors:  Mattias Sandström; Ezgi Ilan; Anna Karlberg; Silvia Johansson; Nanette Freedman; Ulrike Garske-Román
Journal:  EJNMMI Phys       Date:  2015-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.